Breast Cancer



Breast Cancer

Title: CALGB 40502: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound

Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast

Cancer.

Purpose: To compare the anticancer effects and side effects of these three different chemotherapy drugs given on a weekly schedule in

combination with bevacizumab.

Eligibility Subjects must be 18 years or older with invasive breast cancer; Stage IV or Stage IIB, not agreeable to local therapy.

Principal Investigator: Truica, Cristina

Phase: III

For more information, contact: Hagy, Melissa

Telephone Number: 410-601-9083

Email mhagy@

Approved Enrollment Number: 10

Current Enrollment: 0

Breast Cancer

Title: SWOG S0622, Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant

Metastatic Breast Cancer.

Purpose: This study is investigational and is being done to find out if taking the drug dasatinib by mouth by either of two different

dosing schedules will help control cancer and whether it will affect the bones.

Eligibility Patients who have stage IV breast cancer which is bone-predominant. Patients may have 0 to 1 prior chemotherapy regimens

for metastatic disease. Patients who are ER and/or PgR+ must have progressed on at least one hormonal therapy in metastatic

setting. Measurable or non-measurable disease. Zubrod performance status 0-2. Only adults older than 18 can participate.

EKG with OTc ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download